Zealand Pharma A/S has received €3 million in milestone payments from the Helsinn Group of Switzerland following progress in the early-stage development of a new peptide drug for the treatment of diarrhoea induced by chemotherapy. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
